Ligand-mimetic anti-aIIbβ3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells

[1]  M. Mascelli,et al.  Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications , 2009, Pathology & Oncology Research.

[2]  D. Elder,et al.  Integrin Distribution in Malignant Melanoma : Association of the ß 3 Subunit with Tumor Progression 1 , 2006 .

[3]  E. Raso,et al.  Platelet-Mimicry of Cancer Cells: Epiphenomenon with Clinical Significance , 2005, Oncology.

[4]  B. Döme,et al.  Parallel expression of αIIbβ3 and αvβ3 integrins in human melanoma cells upregulates bFGF expression and promotes their angiogenic phenotype , 2005 .

[5]  A. Bosserhoff,et al.  Integrin signaling in malignant melanoma , 2005, Cancer and Metastasis Reviews.

[6]  E. Danen.  Integrins: regulators of tissue function and cancer progression. , 2005, Current pharmaceutical design.

[7]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[8]  D. Griggs,et al.  A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis , 2004, Clinical & Experimental Metastasis.

[9]  C. Bode,et al.  Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa (αIIbβ3, CD41/CD61) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[10]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[11]  J. Tímár,et al.  Expression and function of the high affinity αIibβ3 integrin in murine melanoma cells , 1998, Clinical & Experimental Metastasis.

[12]  L. Languino,et al.  Integrin signaling in cancer. , 2004, Cancer treatment and research.

[13]  F. Fauvel-Lafève,et al.  Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of αvβ3 and αIIbβ3 antagonists , 2004, Clinical & Experimental Metastasis.

[14]  C. Carman,et al.  Integrin avidity regulation: are changes in affinity and conformation underemphasized? , 2003, Current opinion in cell biology.

[15]  S. Mousa,et al.  Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454 , 2003, Thrombosis and Haemostasis.

[16]  G. Tucker.  Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[17]  L. Ellis,et al.  αvβ3 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice , 2003 .

[18]  E. Raso,et al.  Role for β3 integrins in human melanoma growth and survival , 2002 .

[19]  J. Tímár,et al.  Multiple Roles for Platelet GPIIb/IIIa and αvβ3 Integrins in Tumor Growth, Angiogenesis, and Metastasis , 2002 .

[20]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[21]  E. Raso,et al.  Ectopic αIIbβ3 Integrin Signaling Involves 12-Lipoxygenaseand PKC-mediated Serine Phosphorylation Events in Melanoma Cells , 2001, Thrombosis and Haemostasis.

[22]  K. Mikecz.  Vitaxin applied molecular evolution. , 2000, Current opinion in investigational drugs.

[23]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  C. Carron,et al.  Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. , 2000, The Journal of endocrinology.

[25]  R. Jordan,et al.  Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins , 1998 .

[26]  R. Jordan,et al.  Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. , 1998, Circulation.

[27]  J. Brugge,et al.  Regulation of the pp72syk protein tyrosine kinase by platelet integrin αIIbβ3 , 1997 .

[28]  B. Autran,et al.  Analysis by flow cytometry of tyrosine-phosphorylated proteins in activated T-cell subsets on whole blood samples. , 1997, Cytometry.

[29]  J. Tímár,et al.  The High Affinity αIIbβ3 Integrin Is Involved in Invasion of Human Melanoma Cells , 1997 .

[30]  M A Horton,et al.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.

[31]  J. Brugge,et al.  Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3. , 1997, The EMBO journal.

[32]  J. Ring,et al.  Immunoreactivity of glycoprotein lib is present in metastasized but not in non‐metastasized primary malignant melanoma , 1996, The British journal of dermatology.

[33]  M. Ginsberg,et al.  Breaking the Integrin Hinge , 1996, The Journal of Biological Chemistry.

[34]  D. Phillips,et al.  Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation. , 1996, The Journal of biological chemistry.

[35]  J. Brugge,et al.  Adhesive signaling in platelets. , 1994, Current opinion in cell biology.

[36]  D. Elder,et al.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.

[37]  J. Hoxie,et al.  Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. , 1985, The Journal of biological chemistry.